DEF 14A: Cognition Therapeutics Seeks Stockholder Approval for Director Elections and Auditor Ratification at 2024 Annual Meeting

Cognition Therapeutics is holding its 2024 Annual Meeting of Stockholders virtually on June 7, 2024, to vote on the election of two Class III directors and the ratification of Ernst & Young LLP as its independent auditor.

Summary

• Cognition Therapeutics, Inc. will hold its 2024 Annual Meeting of Stockholders on June 7, 2024, at 9:00 a.m. Eastern Time, in a virtual format.
• Stockholders of record as of April 15, 2024, are entitled to vote.
• The meeting will address the election of Jack A. Khattar and Dr. Brett P. Monia as Class III directors for terms expiring in 2027.
• Stockholders will also vote to ratify the appointment of Ernst & Young LLP (EY) as the company's independent registered public accounting firm for the 2024 fiscal year.
• The Board of Directors recommends voting FOR the election of the director nominees and FOR the ratification of EY's appointment.
• The company completed a follow-on public offering receiving gross proceeds of $13.2 million without any associated warrants or other investor incentives.
• Topline results from the Phase 2 SHINE Study of CT1812 in mild-to-moderate Alzheimers disease are expected mid-2024.
• Topline results from the Phase 2 SHIMMER Study in mild-to-moderate dementia with Lewy bodies (DLB) are expected in 2H2024.
• John Doyle was appointed to the role of Chief Financial Officer.

Sentiment

Score: 7

Explanation: The document is primarily informational and procedural, with a neutral to slightly positive tone due to the mention of clinical trial progress and a recent successful public offering. The sentiment is generally stable and reflects standard corporate communications.

Positives

• The company completed a follow-on public offering receiving gross proceeds of $13.2 million without any associated warrants or other investor incentives.
• The Board is committed to fostering a strong culture of compliance and ethical conduct.
• The Board supports managements promotion of a corporate culture of integrity, ethical behavior and compliance with laws and regulations and for ensuring that our culture and strategy are aligned.
• The company strives to create a workplace culture that supports a diverse, multi-cultural workforce, treats individuals fairly, and provides an inclusive environment where all employees are empowered to contribute and succeed.

Risks

• The document outlines the standard risks associated with director elections and auditor ratification, but does not explicitly detail any specific, immediate risks to the company beyond those inherent in its business.

Future Outlook

Topline results from the Phase 2 SHINE Study of CT1812 in mild-to-moderate Alzheimers disease are expected mid-2024, and topline results from the Phase 2 SHIMMER Study in mild-to-moderate dementia with Lewy bodies (DLB) are expected in 2H2024.

Management Comments

• We are pleased to invite you to attend Cognition Therapeutics, Inc.s 2024 Annual Meeting of Stockholders, or the Annual Meeting, which will be held at 9:00 a.m., Eastern Time, on Friday, June 7, 2024.
• The Annual Meeting will be held in virtual meeting format only.
• We believe that the virtual meeting format enables stockholders to attend and participate from any location around the world at no cost, provides for cost savings to Cognition Therapeutics, Inc., and reduces the environmental impact of our Annual Meeting.
• If you have any questions with respect to voting, please contact our Chief Executive Officer, Lisa Ricciardi, at (412) 481-2210.

Industry Context

The company is operating in the competitive biotechnology industry, focusing on developing therapies for neurodegenerative diseases such as Alzheimer's and dementia with Lewy bodies, as well as geographic atrophy secondary to dry AMD. The announcement highlights ongoing clinical trials and research presentations, reflecting the company's efforts to advance its pipeline in these areas.

Comparison to Industry Standards

• The company's board composition reflects a commitment to diversity, aligning with Nasdaq requirements for listed smaller reporting companies.
• The company's executive compensation practices, including base salaries, annual cash incentives, and long-term equity incentives, are typical for biotechnology companies of its size and stage of development.
• The company's corporate governance practices, such as having independent committees and a code of conduct, are consistent with industry standards for publicly traded companies.

Management Changes

Related Party Transactions

• Entities affiliated with BIOS Memory SPV I, LP purchased an aggregate of 500,095 shares of our common stock through our at-the-market offering, or ATM, program, for which Cantor Fitzgerald & Co. and B. Riley Securities, Inc. served as Sales Agents and for which we received gross proceeds of approximately $525,100.

Stakeholder Impact

• Shareholders are asked to vote on key governance matters, influencing the company's direction.
• Employees are subject to the Code of Conduct, promoting ethical behavior.
• The company's focus on ESG initiatives aims to create long-term value for stakeholders.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will proceed with the 2024 Annual Meeting of Stockholders on June 7, 2024.
• The company will continue to execute its clinical development programs and report topline results from ongoing studies.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Board of Directors, Director Election, Ernst & Young, Auditor Ratification, Corporate Governance, Stockholders, Cognition Therapeutics